KalVista PharmaceuticalsKALV
KALV
About: KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Employees: 150
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
22,781% more call options, than puts
Call options by funds: $15.8M | Put options by funds: $69K
50% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]
37% more capital invested
Capital invested by funds: $467M [Q4 2024] → $640M (+$173M) [Q1 2025]
29% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 35
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
1.22% less ownership
Funds ownership: 111.68% [Q4 2024] → 110.46% (-1.22%) [Q1 2025]
2% less funds holding
Funds holding: 130 [Q4 2024] → 128 (-2) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$19
47%
upside
Avg. target
$26
98%
upside
High target
$30
131%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Serge Belanger | 116%upside $28 | Buy Reiterated | 8 Apr 2025 |
Citizens Capital Markets Jonathan Wolleben | 47%upside $19 | Market Outperform Reiterated | 26 Mar 2025 |
Jones Trading Debanjana Chatterjee | 131%upside $30 | Buy Maintained | 26 Mar 2025 |
Financial journalist opinion
Based on 7 articles about KALV published over the past 30 days
Neutral
Reuters
1 day ago
US FDA extends review of KalVista's swelling disorder drug due to heavy workload
The U.S. Food and Drug Administration extended the review of KalVista Pharmaceuticals' drug for a type of hereditary swelling disorder due to heavy workload and limited resources, the company said on Friday.
Neutral
Business Wire
1 day ago
KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it will not meet the PDUFA goal date for the New Drug Application (NDA) for sebetralstat, the Company's investigational oral on-demand treatment for hereditary angioedema (HAE). The FDA notified the Company on June 13, 2025, that the previously disclosed June 17, 2025 PDUFA goal date will not be met d.
Neutral
Business Wire
1 week ago
KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the acceptance of six scientific abstracts at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 taking place in Glasgow, United Kingdom from June 13–16, 2025. Details are as follows: Friday, June 13 Potential for Sebetralstat to Address Pseudo-allergic Reaction Burden Secondary to Icatibant in HAE (D1.324): Sally L. Hampton, Paul K. Audhya, Michael D.
Neutral
Business Wire
1 week ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly-hired employees inducement options to purchase an aggregate of 50,000 shares of KalVista common stock on June 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on.
Neutral
Business Wire
1 week ago
KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new sebetralstat findings related to time to end of progression of hereditary angioedema (HAE) attacks, and the effectiveness of treatment of attacks considered the most debilitating by patients, mucosal attacks, and attacks that have progressed in severity after a treatment delay. These data were presented at two congresses taking place concurrently: the 14th C1-inhibitor Defic.
Neutral
Business Wire
2 weeks ago
KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at 8:45 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentation. About KalVista Pharmaceuticals, Inc. KalV.
Neutral
Business Wire
3 weeks ago
KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that it will present new sebetralstat data at two upcoming congresses taking place concurrently from May 29–June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, and the Eastern Allergy Conference (EAC) in Palm Beach, Florida. The presentations will include new findings on the potential of sebetralstat to rapidly relieve symptoms and halt.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today announced that the compensation committee of KalVista's board of directors granted three newly-hired employees inducement options to purchase an aggregate of 14,000 shares of KalVista common stock on May 1, 2025 as inducements material to each employee entering into employment with KalVista. The options have an exercise price that is equal to the closing price of KalVista common stock on.
Neutral
Business Wire
1 month ago
KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at the Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 11:30 a.m. ET. A live webcast of the presentation will be available on the Company's website at www.kalvista.com. An audio archive will be available on KalVista's website for 30 days following the presentations. About KalVista Pharmaceuticals, Inc. KalVista.
Positive
Seeking Alpha
2 months ago
KalVista: Poised For Rare Disease Transformation
KalVista's lead asset, sebetralstat, is nearing FDA approval, targeting hereditary angioedema with a first-in-class oral treatment, presenting a significant market opportunity. Strong financial position with $253.2 million in cash, bolstered by $160 million in recent financing, ensures readiness for commercialization. Strategic partnerships, including a licensing deal with Kaken Pharmaceutical in Japan, and successful pediatric trial progress, de-risk and expand market potential.
Charts implemented using Lightweight Charts™